Pharmaceuticals
Nanoform Finland Plc, Interim Report January - September 2020, November 27th, 2020 at 08:00 a.m. Finnish time
HELSINKI, Nov. 27, 2020 /PRNewswire/ -- Strong momentum continues: first GMP campaign initiated, first dosing in humans to start before year-end, all near-term business targets set out in IPO to be achieved ahead of schedule, new global major pharma client signed, two new PoC projects started, on...
2020-11-27 14:30
1511
European Medicines Agency Validates Application for Tepotinib for the Treatment of Advanced NSCLC with METex14 Skipping Alterations
DARMSTADT, Germany, Nov. 27, 2020 /PRNewswire/ -- Merck, a leading science and technology company, today announced that the European Medicines Agency (EMA) has validated for review, the application for tepotinib for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) ...
2020-11-27 08:42
700
Luye Pharma and Distriphil Enter Exclusive Distribution Partnership in the Philippines with Joint Commitment to Raising Mental Health Awareness
* Luye Pharma grants Distriphil exclusive distribution and marketing rights for Seroquel® and Seroquel XR® in the Philippines * Two companies pledge to make joint effort to raise awareness of mental health issues as part of the "We Care About Mental Health" initiative SHANGHAI, Nov. 26, 2020 ...
2020-11-26 16:44
1086
Interim report, May-October 2020/21
STOCKHOLM, Nov. 26, 2020 /PRNewswire/ -- In Elekta's second quarter, we managed to perform better than the overall radiotherapy market both in terms of orders and revenue despite continuous challenging circumstances. We also improved margins and stabilized cash flow. The launch of our new Harmony...
2020-11-26 15:01
3251
Approval of Phase I/II Clinical Trial of ATG-016 (Eltanexor), a Second Generation Selective Inhibitor of Nuclear Export (SINE), in Mainland China for the Treatment of Myelodysplastic Syndrome
SHANGHAI and HONG KONG, Nov. 26, 2020 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", HKSE stock code: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-inclass therapeutics in hematolog...
2020-11-26 14:04
2116
Approval of Phase I/II Clinical Trial of ATG-016 (Eltanexor), a Second Generation Selective Inhibitor of Nuclear Export (SINE), in Mainland China for the Treatment of Myelodysplastic Syndrome
SHANGHAI and HONG KONG, Nov. 26, 2020 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", HKSE stock code: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-inclass therapeutics in hematolog...
2020-11-26 10:32
940
Sirtex Medical and China Grand Pharmaceutical announce SIR-Spheres® Y-90 resin microspheres milestone
SIR-Spheres® new drug application is accepted by the National Medical Products Administration of China WOBURN, Mass., Nov. 26, 2020 /PRNewswire/ -- Sirtex Medical ("Sirtex"), a leading manufacturer of targeted liver cancer therapies, announced today that Sirtex with the support of its shareh...
2020-11-26 01:17
917
Ascentage Pharma Announces First Patient Dosed in Europe in the Phase Ib/II Study of the Bcl-2 inhibitor APG-2575 in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
SUZHOU, China and ROCKVILLE, Md., Nov. 25, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that a Phase Ib/II clinical ...
2020-11-25 08:27
736
MedAlliance announces successful completion of enrolment in ISABELLA clinical trial for the treatment of failing AV fistulas in hemodialysis patients
NYON, Switzerland, Nov. 25, 2020 /PRNewswire/ -- MedAlliance has announced completion of patient enrolment in theISABELLA Clinical Trial with SELUTION SLR™ 018 DEB (drug-eluting balloon) for the treatment of dysfunctional AV fistulas in end-stage renal failure patients undergoing hemodialysis. SE...
2020-11-25 08:00
788
RedHill Biopharma to Present at Evercore ISI HealthCONx and Piper Sandler Healthcare Conferences
TEL AVIV, Israel and RALEIGH, N.C., Nov. 25, 2020 /PRNewswire/ -- RedHill
Biopharma Ltd.
2020-11-25 07:00
1261
Almirall announces collaborations with the University of South Australia and Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
BARCELONA, Spain, Nov. 25, 2020 /PRNewswire/ -- AlmirallShare
2020-11-25 06:00
3105
The cost of one dose of the Sputnik V vaccine will be less than $10 for international markets
RDIF continues expanding existing agreements with international manufacturing partners to produce the vaccine for more than 500 million people in 2021 MOSCOW, Nov. 25, 2020 * The cost of one dose of the Sputnik V vaccine for international markets will be less than$10. Sputnik V is a two dose ...
2020-11-25 04:38
717
Second interim analysis of clinical trial data showed a 91.4% efficacy for the Sputnik V vaccine on day 28 after the first dose; vaccine efficacy is over 95% 42 days after the first dose
MOSCOW, Nov. 24, 2020 /PRNewswire/ -- * The efficacy of the Sputnik V vaccine is 91.4%, based on the second interim analysis of data obtained 28 days after administering the first dose (7 days after the second dose). * Calculation was based on the analysis of data on volunteers (n = 18,794) ...
2020-11-24 22:14
745
New Centre for Medicines Research (CMR) Clinical Factbook From Clarivate Highlights Increasing Cost and Complexity of Phase II Trials
Pharmaceutical clinical industry report highlights factors impacting volume, cost and duration of Phase II trials LONDON, Nov. 24, 2020 /PRNewswire/ -- Clarivate Plc (NYSE:CCC), a global leader in providing trusted information and insights to accelerate the pace of innovation, today announced t...
2020-11-24 16:05
3523
Koru Lifescience preparing to send drug compounds to preclinical and clinical trials based on their study for Covid-19
AUCKLAND, New Zealand, Nov. 24, 2020 /PRNewswire/ -- Koru Lifescience, drug discovery, and advanced formulation research laboratory inAuckland, New Zealand , has identified several known drug compounds of value in their study for a treatment of Covid-19. The study reports shall be published after ...
2020-11-24 04:35
506
3SBio Inc. received milestone payment of USD 4 million upon commencement of phase III clinical program of SEL-212
SHENYANG, China, Nov. 23, 2020 /PRNewswire/ -- Chinese leading biopharmaceutical company, 3SBio Inc.(01530.HK, the "Company"), announced today that Selecta Biosciences, Inc. (Nasdaq: SELB), the Company's partner, has commenced the phase III clinical program of a combination therapy involving SEL...
2020-11-23 21:28
4810
Tony Blair Institute and Oracle Launch Africa Vaccine Management in the Cloud
LONDON and REDWOOD SHORES, Calif., Nov. 23, 2020 /PRNewswire/ -- The Tony Blair Institute (TBI) and Oracle have brought cloud technology toAfrica to manage public health programs. Initially,Ghana, Rwanda, and Sierra Leone will use the newOracle Health Management System to create electronic health...
2020-11-23 21:05
3286
GemVax & KAEL reports further positive data from GV1001 Phase II Alzheimer's Disease trial
SEOUL, Nov. 23, 2020 /PRNewswire/ -- GemVax & KAEL Co., Ltd. a clinical stage company developing a novel peptide drug based on telomerase modification has released further positive data at the Korean Dementia Association's Fall Conference from a Phase II trial in Alzheimer's disease of lead candi...
2020-11-23 20:00
733
Fresenius Kabi and ASPEN partner for an expert interview series on omega-3 fatty acid containing parenteral nutrition
BAD HOMBURG, Germany, Nov. 23, 2020 /PRNewswire/ -- Evidence indicates that omega-3 (ω-3) fatty acid containing parenteral nutrition (PN) improves clinical outcomes compared with standard PN in adult patients,1 underlining its role in today's hospitals and clinics. To support continuous health ca...
2020-11-23 19:00
745
Innovent Announces NMPA Granted New Indication Approval for SULINNO® (Adalimumab Injection) in China for the Treatment of Polyarticular Juvenile Idiopathic Arthritis
SAN FRANCISCO and SUZHOU, China, Nov. 23, 2020 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseas...
2020-11-23 18:34
5318
Week's Top Stories
Most Reposted
Raffles Hotel Singapore takes its legendary guest experience to the next level with Adyen
[Picked up by 135 media titles]
2020-11-24 14:49Singapore Fintech startup Sleek secures US $4M from Enterprise Singapore's SEEDS Capital and business angels
[Picked up by 118 media titles]
2020-11-24 09:00
Apigate Enables NJOI's Content to be Purchased on Boost
[Picked up by 116 media titles]
2020-11-25 08:00Taiwan Expo Online in Malaysia Now
[Picked up by 113 media titles]
2020-11-25 17:17
Bank-Genie partners with Cufa to roll-out digital banking for Myanmar credit unions
[Picked up by 112 media titles]
2020-11-24 09:00Most Read
Manulife Singapore Gives Back to Healthcare Workers with Complimentary Passes to Manulife Sky Nets
2020-11-23 20:16
14445
LAIX Inc. to Hold 2020 Annual General Meeting on December 30, 2020
2020-11-21 05:01
10313